Cost-Effectiveness of Alemtuzumab In The Treatment of Relapsing Forms of Multiple Sclerosis In The United States and Societal Spillover Effects
Abstract
Authors
V Chirikov I Ma N Joshi D Patel A Smith C Giambrone N Cornelio L Hashemi